Palonosetron
The newest agent in the class of 5-HT3 receptor antagonists (5-HT3RAs), Palonosetron differs from other agents in its class by its higher receptor-binding affinity and longer half-life.As effective as other 5-HT3RAs in the prevention of acute CINV and is more effective in the prevention of delayed CINV
The recommended dose of Palonsetron is 0.25mg infused intravenously over 30 seconds as a single dose 30 minutes before the start of chemotherapy. It should not be mixed with other drugs. Doses of palonsetron should not be repeated in less than 7 days due to the long half-life of the drug.
Hypersensitivity. Previous hypersensitivity reactions to other selective 5-HT3 receptor antagonists (granisetron and ondansetron). It should be administered with caution in patients who have or may develop prolongation of cardiac conduction intervals, particularly QTc. Such patients include those with hypokalemia or hypomagnesemia, patients taking diuretics with the potential for inducing electrolyte abnormalities, patients with congenital QT syndrome, patients taking antiarrhythmic drugs or ot
It should be used during pregnancy only if clearly needed (Category B). Safety and efficacy have not been established in patients younger than 18 years.
Headache and constipation.
Decreased therapeutic effect of tramadol.
